Skip to content

Effect of snoRNA on lung adenocarcinoma and its mechanism

Effect of snoRNA on lung adenocarcinoma and its mechanism

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100054369
Enrollment
Unknown
Registered
2021-12-16
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung adenocarcinoma

Interventions

Gold Standard:Pathology
Index test:RT&#32
was&#32
used&#32
to&#32
the&#32
expression&#32
of&#32
and&#32
in&#32
cancer&#32

Sponsors

Qingdao Municipal Hospital affiliated to Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have been diagnosed with primary lung adenocarcinoma; 2. All patients did not receive radiotherapy, chemotherapy and targeted therapy before surgery; 3. The patient signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Abnormal liver and kidney function; 2. Combined with other malignant tumors; 3. Combined with bronchiectasis, lung abscess, asthma, COPD, tuberculosis, pulmonary fibrosis and other lung diseases.

Design outcomes

Primary

MeasureTime frame
Area Under the Curve of Receiver Operating Characteristic;

Countries

China

Contacts

Public ContactHan Wei

Qingdao Municipal Hospital affiliated to Qingdao University

hanw@qdu.edu.cn18561857838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026